Two Sigma Investments, LP Recursion Pharmaceuticals, Inc. Transaction History

Two Sigma Investments, LP

$50.6 Billion
Q2 2025

A detailed history of Two Sigma Investments, LP transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,167,813 shares of RXRX stock, worth $6.45 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,167,813

Previous 1,152,626 1.32%

Holding current value

$6.45 Million

Previous $6.1 Million 3.08%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.97 - $5.84 $60,292 - $88,692	15,187 Added 1.32%	1,167,813 $5.91 Million
Q1 2025 May 15, 2025	SELL	$5.29 - $10.87 $2.69 Million - $5.52 Million	-507,883 Reduced 30.59%	1,152,626 $6.1 Million
Q4 2024 Feb 14, 2025	BUY	$5.7 - $8.27 $360,302 - $522,754	63,211 Added 3.96%	1,660,509 $11.2 Million
Q3 2024 Nov 14, 2024	BUY	$5.92 - $8.6 $1.01 Million - $1.47 Million	171,056 Added 11.99%	1,597,298 $10.5 Million
Q2 2024 Aug 14, 2024	BUY	$7.35 - $10.05 $3.89 Million - $5.32 Million	529,762 Added 59.09%	1,426,242 $10.7 Million
Q1 2024 May 15, 2024	BUY	$9.13 - $15.52 $3.32 Million - $5.65 Million	363,840 Added 68.31%	896,480 $8.94 Million
Q4 2023 Feb 14, 2024	BUY	$5.09 - $10.79 $714,203 - $1.51 Million	140,315 Added 35.76%	532,640 $5.25 Million
Q3 2023 Nov 14, 2023	BUY	$6.59 - $15.86 $2.59 Million - $6.22 Million	392,325 New	392,325 $3 Million
Q1 2023 May 15, 2023	BUY	$6.42 - $9.64 $866,956 - $1.3 Million	135,040 Added 184.73%	208,143 $1.39 Million
Q4 2022 Feb 14, 2023	BUY	$7.16 - $12.7 $523,417 - $928,408	73,103 New	73,103 $563,000
Q2 2022 Aug 15, 2022	SELL	$5.04 - $9.26 $1.01 Million - $1.85 Million	-200,131 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.16 - $18.03 $1.23 Million - $3.61 Million	200,131 New	200,131 $1.43 Million

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $996M
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Recursion Pharmaceuticals, Inc. Transaction History